Sequenom News

Scope: Upside potential is ~50%; downside risk is ~15%. Context: Market has not appreciated the non-linear growth phase that Sequenom is in.

Our next company and closing out our healthcare conference will be Sequenom. Speaking today from the company will be Paul Maier, Chief Financial Officer and Dirk van den Boom, Executive Vice President - R&D and Chief Technology Officer.

Shares of Sequenom Inc. extended their recent gains Monday after a Credit Suisse analyst upgraded the stock, citing expanded insurance coverage for its MaterniT21 Plus Down syndrome test.

The firm currently has a $4.50 target price on the stock, up from their previous target price of $4.00. Shares of Sequenom traded up 5.69% during mid-day trading on Monday, hitting $4.27. Sequenom has a one year low of $2.65 and a one year high of $5.83. The stock's 50-day moving average is currently $4.14. The company's market cap is $491.2 ... (more)

Jackpotpennystocks.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:- Sequenom, Inc.

Bluefin Investment Management is a value-oriented hedge fund founded and managed by Brian K. Russell.

Few sectors see as many stocks gaining in the double-digits each week as health care.

Two of Dell's largest shareholders, Carl Ichan and Southeastern Asset Management, told the company's board they will vote against its plan to go private.

Hello. Welcome to Sequenom, Inc. First Quarter 2013 Earnings Conference Call. All participants will be in a listen-only mode.

Sequenom, Inc. , a life sciences company providing innovative genetic analysis solutions, today reported revenue of $38.5 million for the first quarter of 2013, an increase of 158% compared to revenue of $14.9 million for the first quarter of 2012.

Since my last article analyzing Sequenom's financials and modeling its forward performance here , the stock has trended down fairly strongly.

The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com . An audio replay will be available for 30 days following the initial presentation web cast.

Arrayit Corporation , a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide, has been a leader in the microarray market for some time, having been featured on popular documentaries like PBS' NOVA series.

There's been plenty of great press -- you might even say hype -- about IBM's "DNA transistor," a new type of gene sequencing technology that had come out of the company's labs.